CTKB Cytek Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTKB

Price (delayed)

$5.68

Market cap

$738.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.62

Enterprise value

$678.22M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 18
Highlights
The debt has contracted by 8% YoY
The company's revenue rose by 5% YoY
The gross margin has grown by 2.9% from the previous quarter but it has contracted by 2.2% YoY
The quick ratio has contracted by 15% YoY and by 4.6% from the previous quarter
Cytek Biosciences's equity has decreased by 15% YoY
Sector: Healthcare
Industry: Medical Devices
Website: https://cytekbio.com
Peers: OBIO OM

Key stats

What are the main financial stats of CTKB

CTKB stock price

How has the Cytek Biosciences stock price performed over time
Intraday
-0.53%
1 week
15.21%
1 month
18.09%
1 year
53.1%
YTD
12.48%
QTD
28.22%

Financial performance

How have Cytek Biosciences's revenue and profit performed over time
Revenue
$206.71M
Gross profit
$110.03M
Operating income
-$44.65M
Net income
-$80.58M
Gross margin
53.2%
Net margin
-39%
CTKB's operating income has plunged by 66% YoY
The operating margin has plunged by 58% YoY
The net income is down by 9% since the previous quarter
The net margin has contracted by 8% from the previous quarter

Price vs fundamentals

How does CTKB's price correlate with its fundamentals

Growth

What is Cytek Biosciences's growth rate over time

Valuation

What is Cytek Biosciences stock price valuation
CTKB P/E details
P/E
N/A
P/B
2.28
P/S
3.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.28
Cytek Biosciences's EPS has decreased by 9% from the previous quarter
CTKB's price to book (P/B) is 43% higher than its last 4 quarters average of 1.6 but 18% lower than its 5-year quarterly average of 2.8
Cytek Biosciences's equity has decreased by 15% YoY
The P/S is 43% below the 5-year quarterly average of 6.3 but 33% above the last 4 quarters average of 2.7
The company's revenue rose by 5% YoY

Efficiency

How efficient is Cytek Biosciences business performance
The return on invested capital has declined by 19% since the previous quarter
Cytek Biosciences's return on equity has decreased by 13% QoQ
Cytek Biosciences's return on assets has decreased by 12% QoQ
Cytek Biosciences's ROS has decreased by 12% from the previous quarter

Dividends

What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTKB.

Financial health

How did Cytek Biosciences financials performed over time
The quick ratio has contracted by 15% YoY and by 4.6% from the previous quarter
CTKB's current ratio is down by 14% year-on-year and by 4.5% since the previous quarter
The debt is 96% less than the equity
Cytek Biosciences's equity has decreased by 15% YoY
The debt has contracted by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.